SalBenz-1

SalBenz-1 appears to be an experimental **salicylanilide derivative** reported in preclinical anticancer research rather than a marketed or clinically developed therapeutic. Based on the provided publication context, it belongs to a series of substituted salicylanilides evaluated against **U87 human glioblastoma** cells, where the parent compounds and related peptide conjugates reduced cell viability and were associated with **autophagy activation**, including LC3 processing. No clear evidence was provided that SalBenz-1 has an established developer, manufacturer, clinical development program, approved indication, or a fully defined molecular target beyond its characterization as a small-molecule salicylanilide analog with anticancer activity in vitro.